Dr Tony Lockett, Chief Medical Officer at Nevrargenics, explores the future of clinical trials in rare diseases. Clinical trials are in crisis. Over 80% of clinical trials over-run in costs and time and 60% of trials also do not make their endpoint. In this circumstance, it is hardly surprising that despite huge increases in budgets, […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!